Cryo Cell International Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cryo Cell International Inc 's ROA in the second quarter of 2026?
Cryo Cell International Inc recorded a cumulative net loss of $-2 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -4%.

However, within the Healthcare sector 248 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the May 31 2026 quarter, so far to 2928, from total ROA ranking in the first quarter of 2026 at 3369.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(May 31 2026) II. Quarter	(Feb 28 2026) I. Quarter	(Nov 30 2025) IV. Quarter	(Aug 31 2025) III. Quarter	(May 31 2025) II. Quarter
Y / Y Total Assets Change	-5.79 %	-5.43 %	-4.56 %	0.37 %	2.99 %
Y / Y Net Income Change	55.88 %	-83.35 %	-	-28.74 %	-45.75 %
Net Income (TTM) in million	-2	-3	-2	0	0
Return On Assets (TTM)	-4 %	-4.26 %	-3.83 %	-0.74 %	-0.27 %
CCEL's Total Ranking	# 2928	# 3369	# 2679	# 2605	# 2533
Total Assets (TTM) in million	61	61	62	63	64
Seq. Total Assets Change	-0.29 %	-1.37 %	-2.28 %	-1.97 %	0.09 %
Seq. Net Income Change	1077.27 %	-	-	110.64 %	25.78 %

CCEL's 5 Years Annual ROA >> Back to CCEL Management Effectiveness >> Compare CCEL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 30
Sector	# 249
Overall	# 2894

Return On Assets Statistics
High	Average	Low
62.85 %	1.88 %	-46.18 %
(Aug 31 2015)		(Nov 30 2012)

Financial Statements
Cryo Cell International Inc 's Assets	$ 61 million	CCEL's Balance sheet
Cryo Cell International Inc 's Income	$ 1 million	Quarterly CCEL's Income Statement
CCEL's Income by Division		See CCEL's Income by Division

Annual Return On Assets	(Nov 30 2025) FY 2025	(Nov 30 2024) FY 2024	(Nov 30 2023) FY 2023	(Nov 30 2022) FY 2022	(Nov 30 2021) FY 2021
Y / Y Total Assets Change	-4.56 %	6.18 %	-5.68 %	7 %	8.29 %
Total Assets in million	62	65	61	65	60
Y / Y Net Income Change	-	-	-	33.02 %	-42.52 %
Net Income in million	-2	0	-10	3	2
Annual Return On Assets	-3.94 %	0.62 %	-15.63 %	4.29 %	3.45 %

CCEL's 5 Years Annual ROA >> Back to CCEL Management Effectiveness >> Compare CCEL ROA to its Competitors

More Return On Assets Ratios
CCEL's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CCEL's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CCEL's Competitors
Subscribers only: Roa for Cryo Cell International Inc 's Suppliers
Subscribers only: Return On Assets for CCEL's Customers

You may also want to know
CCEL's Roi	CCEL's Inventory Turnover Ratio	CCEL's Growth Rates	CCEL's Dividend Comparisons
	CCEL's Profitability Ratios	CCEL's Asset Turnover Ratio	CCEL's Dividend Growth
CCEL's Roe	CCEL's Valuation Ratios	CCEL's Financial Strength Ratios	CCEL's Dividend Payout Ratio

Companies with similar Return On Assets at May 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-19T05:06:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.